ATA91797A - Eine das vwf-propeptid enthaltende pharmazeutische präparation - Google Patents

Eine das vwf-propeptid enthaltende pharmazeutische präparation

Info

Publication number
ATA91797A
ATA91797A AT0091797A AT91797A ATA91797A AT A91797 A ATA91797 A AT A91797A AT 0091797 A AT0091797 A AT 0091797A AT 91797 A AT91797 A AT 91797A AT A91797 A ATA91797 A AT A91797A
Authority
AT
Austria
Prior art keywords
pharmaceutical preparation
preparation containing
vwf propeptide
vwf
propeptide
Prior art date
Application number
AT0091797A
Other languages
English (en)
Other versions
AT405485B (de
Inventor
Hans-Peter Schwarz
Katalin Dr Varadi
Peter Dr Turecek
Hendrik Coenraad Hemker
Suzette Lucette Beguin
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0091797A priority Critical patent/AT405485B/de
Application filed by Immuno Ag filed Critical Immuno Ag
Priority to AU79156/98A priority patent/AU744643B2/en
Priority to CA002288737A priority patent/CA2288737A1/en
Priority to DE69802918T priority patent/DE69802918T2/de
Priority to EP98929378A priority patent/EP0977584B1/de
Priority to AT98929378T priority patent/ATE210455T1/de
Priority to ES98929378T priority patent/ES2168766T3/es
Priority to JP50022099A priority patent/JP4335978B2/ja
Priority to PCT/EP1998/003090 priority patent/WO1998053848A1/en
Priority to US09/424,498 priority patent/US7005502B1/en
Publication of ATA91797A publication Critical patent/ATA91797A/de
Application granted granted Critical
Publication of AT405485B publication Critical patent/AT405485B/de
Priority to NO19995843A priority patent/NO324064B1/no
Priority to US11/218,406 priority patent/US7557188B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT0091797A 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation AT405485B (de)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation
PCT/EP1998/003090 WO1998053848A1 (en) 1997-05-28 1998-05-26 PHARMACEUTICAL PREPARATION COMPRISING vWF PROPEPTIDE
DE69802918T DE69802918T2 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat
EP98929378A EP0977584B1 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat
AT98929378T ATE210455T1 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat
ES98929378T ES2168766T3 (es) 1997-05-28 1998-05-26 Preparacion farmaceutica que incluye el propeptido vwf.
AU79156/98A AU744643B2 (en) 1997-05-28 1998-05-26 Pharmaceutical preparation comprising vWF propeptide
CA002288737A CA2288737A1 (en) 1997-05-28 1998-05-26 Pharmaceutical preparation comprising vwf propeptide
US09/424,498 US7005502B1 (en) 1997-05-28 1998-05-26 Pharmaceutical preparation comprising vWF propeptide
JP50022099A JP4335978B2 (ja) 1997-05-28 1998-05-26 ｖＷＦプロペプチドを含む医薬調製物
NO19995843A NO324064B1 (no) 1997-05-28 1999-11-29 Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav
US11/218,406 US7557188B2 (en) 1997-05-28 2005-09-01 Methods of treating blood coagulation disorders using a pharmaceutical preparation comprising vWF propeptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation

Publications (2)

Publication Number Publication Date
ATA91797A true ATA91797A (de) 1999-01-15
AT405485B AT405485B (de) 1999-08-25

Family

ID=3502803

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT98929378T ATE210455T1 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98929378T ATE210455T1 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat

Country Status (10)

Country Link
US (2) US7005502B1 (de)
EP (1) EP0977584B1 (de)
JP (1) JP4335978B2 (de)
AT (2) AT405485B (de)
AU (1) AU744643B2 (de)
CA (1) CA2288737A1 (de)
DE (1) DE69802918T2 (de)
ES (1) ES2168766T3 (de)
NO (1) NO324064B1 (de)
WO (1) WO1998053848A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1240900B1 (de) 1999-12-24 2009-05-06 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
BRPI0519562A2 (pt) 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
WO2009086400A2 (en) * 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
DK2349314T3 (da) * 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
ES2713270T3 (es) * 2008-10-27 2019-05-20 Baxalta GmbH Modelos de ratón de púrpura trombocitopénica trombótica y métodos para su uso
CN106008697B (zh) 2009-08-20 2020-08-04 百深公司 纯化vwf以增加非-脂质包封的病毒的去除
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
NL2017452A (en) 2015-10-02 2017-04-11 Asml Netherlands Bv Metrology method and apparatus, computer program and lithographic system
DK3648788T3 (da) 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf
PT3648787T (pt) 2017-07-07 2025-01-20 Takeda Pharmaceuticals Co Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante
SG11202009213TA (en) 2018-03-21 2020-10-29 Baxalta Inc Separation of vwf and vwf propeptide by chromatographic methods
BR112021015068A2 (pt) 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited Métodos de tratamento profilático usando vwf recombinante (rvwf)
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
BR112022015326A2 (pt) 2020-02-04 2022-10-11 Takeda Pharmaceuticals Co Tratamento de menorragia em pacientes com doença de von willebrand severa por administração de vwf recombinante

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT350726B (de) 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT378005B (de) 1983-08-20 1985-06-10 Linde Ag Verfahren zum desoxidieren von metallschmelzen
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT398079B (de) 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
JP3133338B2 (ja) 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
AT402788B (de) 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
JPH07330797A (ja) 1994-05-31 1995-12-19 Sumitomo Metal Ind Ltd 新規細胞接着活性ペプチド
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
AT404359B (de) 1996-04-29 1998-11-25 Immuno Ag Gereinigte multimerase
AT404554B (de) 1996-04-29 1998-12-28 Immuno Ag Pharmazeutische präparation
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase

Also Published As

Publication number Publication date
DE69802918D1 (de) 2002-01-24
AU744643B2 (en) 2002-02-28
US7557188B2 (en) 2009-07-07
ES2168766T3 (es) 2002-06-16
WO1998053848A1 (en) 1998-12-03
JP4335978B2 (ja) 2009-09-30
NO324064B1 (no) 2007-08-06
AT405485B (de) 1999-08-25
DE69802918T2 (de) 2003-04-10
EP0977584B1 (de) 2001-12-12
US20060003921A1 (en) 2006-01-05
AU7915698A (en) 1998-12-30
NO995843L (no) 2000-01-27
EP0977584A1 (de) 2000-02-09
US7005502B1 (en) 2006-02-28
ATE210455T1 (de) 2001-12-15
JP2001527579A (ja) 2001-12-25
NO995843D0 (no) 1999-11-29
CA2288737A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
ATE210455T1 (de) Vwf propeptide enthaltendes pharmazeutisches präparat
FI872756A0 (fi) Med laserstraolning fungerande terapeutisk anordning.
ES2000428T3 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
DE69008664D1 (de) Bestrahlung von bluterzeugnissen.
DE3772429D1 (de) Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
DE69814394D1 (de) Verwendung von levobupivacain
FI952169L (fi) Stabiili valmiste veren koagulaatiohäiriöiden hoitamiseksi
NO902411D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer.
ATE132757T1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
IT1238825B (it) Dispositivo per la correzione chirurgica dell'ametropia.
IT9041503A0 (it) Dispositivo per la cura chirurgica dell'ametropia
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
IT1198233B (it) Metodo per la determinazione di anticorpi antisporozoita di p. falciparum nel sangue umano
NO881768D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner.
ATA77095A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen, enthaltend eine aktive gerinnungsfördernde stubstanz
FI844645A0 (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
DK301190A (da) Bioforenelige, stof-specifikke reagenser til behandling af fysiologiske vaesker
ES2081279T3 (es) Utilizacion de 15-desoxiespergualina como medicamento.
DE69000791D1 (de) Therapeutische mittel fuer metabolische knochenkrankheiten.
NO871477D0 (no) Fremgangsmaate for fremstilling av human plasminogenaktivator.
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE3771266D1 (de) Medizinisches instrument zum ausschneiden von knochengewebe.
ES2077698T3 (es) Agente terapeutico para la gangrena diabetica.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee
EIH Change in the person of patent owner
PC Change of the owner

Owner name: BAXALTA INCORPORATED, US

Effective date: 20160623

Owner name: BAXALTA GMBH, CH

Effective date: 20160623

MK07 Expiry

Effective date: 20170528